Today, Roche put out the word that their PD-L1 drug MPDL3280A won the FDA’s coveted breakthrough therapy designation, potentially putting it on an inside track at the agency, which has been hurrying along new medicines in the pipeline.

…read more

Source: Roche partners with Roche on ‘breakthrough’ PD-L1 cancer program


0 No comments